Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Abstract Background Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–targeting antibodies have been evaluated, largely in patient...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin, Fiona Ginty, Anup Sood, Stephen M. Hewitt, Jeffrey Schlom, Raffit Hassan, James L. Gulley
格式: Artigo
語言:Inglês
出版: BMJ Publishing Group 2019-10-01
叢編:Journal for ImmunoTherapy of Cancer
主題:
Thymoma
Immunotherapy
Avelumab
Immune-related adverse events
Immunosuppressive therapy
Anti-PD-L1
在線閱讀:http://link.springer.com/article/10.1186/s40425-019-0723-9
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍